Recruiting

STING AgonistImmunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)

Sponsor:

Thomas Jefferson University

Code:

NCT05705986

Conditions

Relapse Remitting Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Blood Draw

Study Details

Brief summary:

Microparticles (MPs) as a mode of therapeutic delivery can selectively deliver immunomodulatory treatment to the phagocytic cells, particularly dendritic cells (DCs), inducing their tolerogenic phenotype and function and T regulatory (Treg) cell expansion. The study will characterize the in vitro response of cGAMP immunomodulator incapsulated microparticles on the capacity of DCs and Tregs to regulate the inflammatory response.

Conditions

Relapse Remitting Multiple Sclerosis

Study ID

NCT05705986

Start date

Feb 26, 2021

Status verified date

Jan, 2023

Completion date

May, 2024

Anticipated

Primary completion date

May, 2024

Anticipated

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Subjects meeting diagnostic criteria for relapsing remitting multiple sclerosis
2. Between the ages of 18-55
3. Not treated with immunomodulatory therapy, no other neurological diagnosis, no other inflammatory disease

Exclusion Criteria:

-

Study Design

Enrollment

40 participants

Anticipated

Interventions and Outcome Measures

Interventions

Blood Draw

Single blood draw

Primary outcome measure

Characterize cGAMP MP-induced tolerogenic DCs from RRMS patients. [ Time Frame: Baseline ]
Determine the capacity of cGAMP MP-treated DCs to induce iTreg expansion in human in-vitro cultures [ Time Frame: Baseline ]

Central Contacts and Locations

Central contacts

Silva Markovic-Plese, MD, PhD

215-503-6393 Silva.Markovic-Plese@jefferson.edu

Locations

Thomas Jefferson University

Recruiting

Philadelphia, Pennsylvania, United States, 19107

Contacts

Silva Markovic-Plese, MD, PhD

215-503-6393 Silva.Markovic-Plese@jefferson.edu

Principal Investigator:

Silva Markovic-Plese, MD, PhD

More Information

Sponsor

Thomas Jefferson University

Last update posted

Jan 31, 2023

Last verified

Jan, 2023

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Thomas Jefferson University on 2023-01-31.